Home
/
C4 Therapeutics, Inc.
/
Financials
/
Quarterly
C4 Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that C4 Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$11.23M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$6.46M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$7.24M
May 7, 2025
Q1
2023
Sep 30, 2024
$15.36M
Oct 31, 2024
Q3
2025
Sep 30, 2024
$15.36M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$12.01M
Aug 7, 2025
Q1
2023
Jun 30, 2024
$12.01M
Aug 1, 2024
Q1
2025
Mar 31, 2024
$3.04M
May 7, 2025
Q1
2023
Sep 30, 2023
$11.07M
Oct 31, 2024
Q1
2023
Jun 30, 2023
$2.66M
Aug 1, 2024
Q1
2023
Mar 31, 2023
$3.76M
May 8, 2024
Q1
2023
Sep 30, 2022
$6.75M
Nov 1, 2023
Q3
2022
Sep 30, 2022
$6.75M
Nov 3, 2022
Q1
2023
Jun 30, 2022
$13.83M
Aug 8, 2023
Q2
2022
Jun 30, 2022
$13.83M
Aug 4, 2022
Q1
2023
Mar 31, 2022
$7.65M
May 4, 2023
Q3
2022
Sep 30, 2021
$8.50M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$9.78M
Aug 4, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($32.17M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($26.02M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($26.02M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($26.32M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($26.32M)
May 7, 2025
Q2
2025
Mar 31, 2025
($26.32M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($24.67M)
Nov 6, 2025
Q1
2023
Sep 30, 2024
($24.67M)
Oct 31, 2024
Q1
2023
Jun 30, 2024
($17.72M)
Oct 31, 2024
Q2
2025
Jun 30, 2024
($17.72M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($17.72M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($28.36M)
May 7, 2025
Q2
2025
Mar 31, 2024
($28.36M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($28.36M)
Nov 6, 2025
Q1
2023
Sep 30, 2023
($27.04M)
Oct 31, 2024
Q1
2023
Jun 30, 2023
($35.92M)
Oct 31, 2024
Q1
2023
Mar 31, 2023
($34.78M)
Oct 31, 2024
Q3
2022
Sep 30, 2022
($31.96M)
Nov 3, 2022
Q1
2023
Sep 30, 2022
($31.96M)
Nov 1, 2023
Q2
2022
Jun 30, 2022
($27.41M)
Aug 4, 2022
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($34.41M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($28.50M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($29.16M)
May 7, 2025
Q3
2025
Sep 30, 2024
($28.24M)
Nov 6, 2025
Q1
2023
Sep 30, 2024
($28.24M)
Oct 31, 2024
Q1
2023
Jun 30, 2024
($21.44M)
Aug 1, 2024
Q2
2025
Jun 30, 2024
($21.44M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($32.22M)
May 7, 2025
Q1
2023
Sep 30, 2023
($27.81M)
Oct 31, 2024
Q1
2023
Jun 30, 2023
($37.57M)
Aug 1, 2024
Q1
2023
Mar 31, 2023
($36.23M)
May 8, 2024
Q1
2023
Sep 30, 2022
($32.49M)
Nov 1, 2023
Q3
2022
Sep 30, 2022
($32.49M)
Nov 3, 2022
Q1
2023
Jun 30, 2022
($27.38M)
Aug 8, 2023
Q2
2022
Jun 30, 2022
($27.38M)
Aug 4, 2022
Q1
2023
Mar 31, 2022
($31.37M)
May 4, 2023
Q3
2022
Sep 30, 2021
($24.25M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($22.12M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($20.51M)
May 5, 2022
Q3
2021
Sep 30, 2020
($18.35M)
Nov 10, 2021